Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Queensland Health
Covington
Farmers Insurance
Chinese Patent Office
UBS
Teva
Fish and Richardson
Moodys

Generated: August 22, 2017

DrugPatentWatch Database Preview

VIIBRYD Drug Profile

« Back to Dashboard

Which patents cover Viibryd, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Forest Labs Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-nine patent family members in thirty-two countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

Summary for Tradename: VIIBRYD

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list54
Clinical Trials: see list16
Patent Applications: see list27
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIIBRYD at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-001Jan 21, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-002Jan 21, 2011RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VIIBRYD

Drugname Dosage Strength RLD Submissiondate
vilazodone hydrochlorideTablets10 mg, 20 mg, and 40 mgVIIBRYD1/21/2015

Non-Orange Book Patents for Tradename: VIIBRYD

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,624,204Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
7,381,726Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
8,927,552Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
8,318,744Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
7,981,894Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIIBRYD

Country Document Number Estimated Expiration
Canada2782862► Subscribe
China1516699► Subscribe
Hong Kong1066003► Subscribe
Hungary9402806► Subscribe
Hungary0400236► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Mallinckrodt
McKesson
Dow
McKinsey
Farmers Insurance
US Department of Justice
Boehringer Ingelheim
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot